Key Highlights

• X4 Pharmaceuticals added Kelly Gold as a director, expanding the board to six members.

• Gold will serve on the audit committee and brings recent CFO experience from CAMP4 Therapeutics.

• Compensation follows X4’s established policy for non‑employee directors.

• Gold’s prior finance leadership includes roles at Biogen and Deutsche Bank’s healthcare investment banking group.

Board Expansion Announced

X4 Pharmaceuticals has broadened its leadership by welcoming Kelly Gold to the board of directors. The board’s approval of the appointment increases its size and adds depth in financial expertise as the company moves its rare‑disease programs forward.

New Director’s Background

Gold currently holds the chief financial officer role at CAMP4 Therapeutics, a clinical‑stage biopharma focused on rare diseases. Prior to that, she occupied senior finance positions at CAMP4 and earlier served in business development and corporate development capacities. Her career also includes strategic finance work at Biogen and experience in healthcare investment banking with Deutsche Bank.

Audit Committee Role

As a member of the audit committee, Gold will oversee financial reporting and risk management functions. The committee’s work is critical to ensuring robust governance while the company advances clinical trials and prepares for potential product launches.

Compensation and Governance

Gold’s remuneration will be consistent with X4’s standard practice for directors who are not employees. No additional arrangements or conflicts were disclosed in relation to her appointment.

Career Highlights

Before her tenure at CAMP4, Gold spent several years at Biogen, directing financial strategy for late‑stage and marketed rare‑disease programs. She also contributed to healthcare investment banking activities at Deutsche Bank. Gold earned degrees in scientific and engineering disciplines from Queen’s University and holds an MBA from the MIT Sloan School of Management.

Strategic Implications

The addition of Gold underscores X4’s commitment to financial discipline as it advances its clinical portfolio. Her background in corporate finance and rare‑disease therapeutics is expected to support capital allocation decisions and partnership efforts. Stakeholders will monitor how the expanded board influences financial priorities and governance practices.

Market Context

X4 remains a clinical‑stage organization without an approved product at present. The board expansion occurs amid industry pressure for operational efficiency and effective capital use. Gold’s appointment may provide reassurance to investors regarding the company’s focus on sound financial oversight during a pivotal development period.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.